• (PLX AI) – Bayer’s new symptomatic chronic heart failure treatment Verquvo (vericiguat) approved in EU.
  • • Approved for adult patients with reduced ejection fraction who are stabilized after a recent decompensation event requiring intravenous therapy
  • • Studied in a population with a high risk of cardiovascular death or heart failure hospitalization
  • • The sGC-stimulator Verquvo provides a specific approach to managing chronic heart failure following a decompensation event

Quelle: PLX AI